Volume 18, Issue 3, Pages (March 2010)

Slides:



Advertisements
Similar presentations
Fig. 1. Electroporation of interleukin 12 (IL-12) DNA compared with control DNA increases the level of IL-12 expression (picograms/milligrams total protein)
Advertisements

Volume 17, Issue 9, Pages (September 2009)
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies  Ali Mahtabifard,
Molecular Therapy - Oncolytics
IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling  Yuan-Hua Xu, Zheng-Li Li,
Volume 21, Issue 10, Pages (October 2013)
Volume 15, Issue 2, Pages (February 2007)
Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-β Against Choriocarcinoma in Xenografted.
Volume 21, Issue 11, Pages (November 2013)
Volume 16, Issue 1, Pages (January 2008)
Regulation of Human Melanoma Growth and Metastasis by AGE–AGE Receptor Interactions  Riichiro Abe, Tadamichi Shimizu, Hiroshi Sugawara, Hirokazu Watanabe,
by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Volume 15, Issue 12, Pages (December 2007)
Molecular Therapy - Oncolytics
Volume 10, Issue 5, Pages (November 2004)
Volume 21, Issue 8, Pages (August 2013)
Volume 15, Issue 11, Pages (November 2007)
Molecular Therapy - Oncolytics
Einar K. Rofstad, Bjørn A. Graff  Journal of Investigative Dermatology 
Volume 24, Issue 9, Pages (September 2016)
Volume 21, Issue 10, Pages (October 2013)
Volume 7, Issue 2, Pages (February 2003)
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
Volume 18, Issue 9, Pages (September 2010)
The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF  Kathrin Schwager, Teresa Hemmerle, David Aebischer,
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Molecular Therapy - Nucleic Acids
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 22, Issue 5, Pages (May 2014)
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Multiple Functions of the 37/67-kd Laminin Receptor Make It a Suitable Target for Novel Cancer Gene Therapy  Jonathan Scheiman, Jen-Chieh Tseng, Yun Zheng,
Volume 23, Issue 4, Pages (April 2015)
Volume 23, Issue 4, Pages (April 2015)
Marta Vilalta, Marjan Rafat, Amato J. Giaccia, Edward E. Graves 
Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of niemann–pick.
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas
Volume 22, Issue 6, Pages (June 2014)
Volume 16, Issue 6, Pages (June 2008)
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 22, Issue 1, Pages (January 2014)
Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer  Yalei Cui, Xiaoyuan Yang, Xiaobo Zhang  Molecular.
Volume 20, Issue 1, Pages (January 2012)
Volume 19, Issue 3, Pages (March 2011)
Volume 25, Issue 3, Pages (March 2017)
Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell 
Volume 6, Issue 3, Pages (September 2002)
Volume 18, Issue 8, Pages (August 2010)
Volume 24, Issue 1, Pages (January 2016)
Volume 18, Issue 3, Pages (March 2010)
Volume 26, Issue 1, Pages (January 2018)
Volume 23, Issue 1, Pages (January 2015)
Molecular Therapy - Nucleic Acids
Volume 6, Issue 5, Pages (November 2002)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Volume 22, Issue 9, Pages (September 2014)
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
MRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma  Yuhua Wang, Lu Zhang, Zhenghong.
Systemic Administration of Platelets Incorporating Inactivated Sendai Virus Eradicates Melanoma in Mice  Tomoyuki Nishikawa, Li Yu Tung, Yasufumi Kaneda 
Volume 20, Issue 6, Pages (June 2012)
Volume 20, Issue 4, Pages (April 2012)
Volume 21, Issue 3, Pages (March 2013)
Protein Transduction Domain-mediated Delivery of QBP1 Suppresses Polyglutamine- induced Neurodegeneration In Vivo  H Akiko Popiel, Yoshitaka Nagai, Nobuhiro.
Volume 15, Issue 2, Pages (February 2007)
Engraftment of Bone Marrow–derived Stem Cells to the Lung in a Model of Acute Respiratory Infection by Pseudomonas aeruginosa  Joanna Rejman, Carla Colombo,
Molecular Therapy - Nucleic Acids
Presentation transcript:

Volume 18, Issue 3, Pages 635-642 (March 2010) Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli– mediated Cytolytic Therapy and Radiotherapy  Sheng-Nan Jiang, Thuy X Phan, Taek-Keun Nam, Vu H Nguyen, Hyung-Seok Kim, Hee-Seung Bom, Hyon E Choy, Yeongjin Hong, Jung-Joon Min  Molecular Therapy  Volume 18, Issue 3, Pages 635-642 (March 2010) DOI: 10.1038/mt.2009.295 Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Engineering of E.coli k-12 to express and secrete cytolysin A. (a) Map of the bacterial expression plasmid containing the gene encoding aspartate β-semialdehyde dehydrogenase (Asd) and the cytolysin A gene (pAClyA). (b) The E. coli asd::kan strain (HJ1020) was transformed with pAClyA (E. coli pAClyA) or the empty vector containing only the Asd gene (pAsd). The expression and secretion of ClyA (34 kd) was analyzed by western blot using an anti-ClyA antibody. Bacterial pellets (left) and culture media (right) were analyzed. (c) E. coli–expressing ClyA and Lux can lyse blood cells (left) and produce a clear bioluminescent signal in the corresponding area of hemolysis (right). Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Genetically engineered E. coli can target and deliver ClyA to subcutaneously grafted CT26 tumors. (a) Noninvasive in vivo imaging of bacterial bioluminescence in the targeted tumors of representative tumor-bearing mice (n = 2). (b,c) Detection of the 34-kd ClyA protein in CT26 tumor tissues of mice injected with E. coli–expressing ClyA (E. coli pAClyA). The ClyA protein was detected (b) using western blot analysis, and (c) by immunohistochemical and immunofluorescence staining. ClyA, cytolysin A. Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Suppression of tumor growth by engineered E. coli–expressing ClyA. BALB/c mice (n = 15) were inoculated subcutaneously with 106 CT26 cells. When the tumor reached ~150 mm3 in volume or ~10 mm in a diameter, they were injected with PBS or bacteria. (a) Photographs of subcutaneous tumors in mice injected with PBS (control), or 5 × 107 CFU of E. coli carrying empty vector (E. coli pAsd) or the ClyA vector (E. coli pAClyA). Photographs of representative tumors were taken at 12, 17, 21, and 27 days after injection. (b) Effects of the injections of PBS, E. coli pAsd, or E. coli pAClyA on CT26 tumor growth rates (n = 5 each group, *P < 0.05). CFU, colony-forming units; ClyA, cytolysin A; PBS, phosphate-buffered saline. Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Histologic examination of syngeneic CT26 before and after treatment. H&E stain of syngeneic CT26 tumor 4 days after intravenous injection of PBS (control), or 5 × 107 CFU of E. coli carrying empty vector (E. coli pAsd) or the ClyA vector (E. coli pAClyA) (bar = 1 mm). CFU, colony-forming units; H&E, hematoxylin–eosin; PBS, phosphate-buffered saline. Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Effects of combining engineered E. coli therapy with radiation in CT26-bearing mice. BALB/c mice were inoculated subcutaneously with 106 CT26 cells. (a) Photographs of subcutaneous tumors in mice treated with PBS (no treatment) or with a combination of bacteria (BT; 5 × 107 CFU of E. coli pAClyA) and radiation (RT; 21 Gy). Photographs of representative tumors were taken at 12–42 days after the beginning of treatments. (b) Effects on the growth rates of CT26 tumors after treatment with E. coli–expressing ClyA (BT; 5 × 107 CFU) combined with various doses of radiotherapy (RT; 0, 8, 15, 21 Gy). PBS only (filled square), BT only (open square), RT (8 Gy) + BT (filled circle), RT (15 Gy) + BT (open circle) and RT (21 Gy) + BT (filled triangle). (c) Effects on the growth rates of CT26 tumors after treatment with radiation (RT; 21 Gy) and various doses of E. coli–expressing ClyA (0–5 × 107 CFU). PBS only (filled square), RT only (open square), BT (5 × 106 CFU) + RT (filled circle), BT (1 × 107 CFU) + RT (open circle), and BT (5 × 107 CFU) + RT (filled triangle) (n = 5 each group). (d) Kaplan–Meier survival curves between RT (21 Gy) and RT (21 Gy) + BT (5 × 107 CFU) are shown (n = 5 each group). *P < 0.05, **P < 0.01. BT, bacterial therapy; CFU, colony-forming units; PBS, phosphate-buffered saline; RT, radiotherapy. Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Effects of combining engineered E. coli therapy with radiation in B16F10 and 4T1-bearing mice. Nude mice or BALB/c mice were inoculated subcutaneously with 106 B16F10 cells or 106 4T1 cells, respectively. Effects on (a) B16F10 and (b) 4T1 tumor growth after treatment with E. coli–expressing ClyA (5 × 107 CFU) and/or radiation (21 Gy). Controls were treated with PBS (open circle). BT, treatment with E. coli–expressing ClyA only (circle); RT, radiotherapy only (triangle); RT + BT, combination therapy with radiation and E. coli–expressing ClyA (square). (n = 5 each group, *P < 0.05, **P < 0.01). BT, bacterial therapy; CFU, colony-forming units; ClyA, cytolysin A; PBS, phosphate-buffered saline; RT, radiotherapy. Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Effects of E. coli–expressing ClyA on lung metastases. BALB/c mice were injected with CT26 cells that were stably producing firefly luciferase. Mice were intravenously injected with engineered (E. coli pAClyA) or nonengineered bacteria (E. coli pAsd), or PBS at day 5 after the cancer cells were injected. The cooled CCD camera was used to analyze metastasis establishment in lungs of the mice after intraperitoneal injection of 3 mg of D-luciferin per animal. (a) Bioluminescence images of lung metastasis development in mice at 4, 7, and 11 days after each treatment. (b) Lungs were excised from the mice 6 days after the treatments. Top: photographs of representative lungs. Bottom: bioluminescence images of the same lungs. (c) Lung weights and (d) metastasis scores were measured in the mice 6 days after each treatment (n = 3 each group). (e) Kaplan–Meier survival curves are shown (n = 8 each group). *P < 0.05, **P < 0.01. CCD, charge-coupled device; ClyA, cytolysin A; PBS, phosphate-buffered saline. Molecular Therapy 2010 18, 635-642DOI: (10.1038/mt.2009.295) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions